文献速递胸部外周血管CT

COVID-19患者CT上肺血栓栓塞性疾病的范围:与肺实质病变的关系

Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease.
PubMed 文献 · Clin Radiol · 2020-07-10

该回顾性分析纳入27天内100例确诊COVID-19并接受CT肺动脉造影(CTPA)的患者,分析93例可评估检查。肺血栓栓塞性疾病(PTD)总体发生率为44%(41/93),其中小血管PTD占30%(28/93)。D-二聚体升高者占96.8%(90/93),高Wells评分不能区分PTD与非PTD组(p=0.801)。结论提示接受CTPA的COVID-19患者PTD发生率高且缺乏风险分层工具,重症患者需提高PTD怀疑,CT上可能纤维化特征需随访。

要点

  • COVID-19患者CTPA中PTD总体发生率44%(41/93),小血管PTD占30%(28/93)。
  • D-二聚体升高见于96.8%(90/93),但高Wells评分不能区分PTD与非PTD(p=0.801)。
  • 36.6%(34/93)淋巴结增大,其中85.3%(29/34)无其他感染源;17.2%(16/93)有潜在纤维化特征。

核心结论

  • 接受CTPA的COVID-19患者PTD发生率高,且缺乏风险分层工具。
  • 数据提示重症COVID-19患者需提高对PTD的怀疑。
  • CT上同时存在可能纤维化特征提示需要随访。

研究设计与样本

  • 回顾性分析,27天内100例确诊COVID-19患者接受CTPA,排除不确定的CTPA检查后分析93例。
  • 由两名观察者评分肺实质病变模式和范围(包括潜在纤维化特征)、淋巴结增大和胸腔积液,通过第三观察者达成共识。
  • 采用kappa统计评估观察者间一致性,采用Student t检验、卡方检验和Mann-Whitney U检验比较PTD与非PTD亚组的影像特征。

关键影像表现/征象

  • PTD总体发生率41/93(44%),其中小血管PTD 28/93(30%)。
  • 淋巴结增大34/93(36.6%),其中29/34(85.3%)无其他感染源。
  • 潜在纤维化特征16/93(17.2%)。

诊断标准与关键数值

  • D-二聚体升高90/93(96.8%)。
  • 高Wells评分不能区分PTD与非PTD组(p=0.801)。
  • 观察者间一致性:肺实质模式为fair(kappa=0.659),严重程度为excellent(kappa=0.816)。

临床应用与阅片要点

  • 作者认为重症COVID-19患者需提高对PTD的怀疑。
  • 作者认为CT上同时存在可能纤维化特征提示需要随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To report the severity and extent of pulmonary thromboembolic disease (PTD) in COVID-19 patients undergoing computed tomography pulmonary angiography (CTPA) in a tertiary centre.

MATERIALS AND METHODS: This is a retrospective analysis of COVID-19 patients undergoing CTPA over a period of 27 days. The presence, extent, and severity of PTD were documented. Two observers scored the pattern and extent of lung parenchymal disease including potential fibrotic features, as well as lymph node enlargement and pleural effusions. Consensus was achieved via a third observer. Interobserver agreement was assessed using kappa statistics. Student's t-test, chi-squared, and Mann-Whitney U-tests were used to compare imaging features between PTD and non-PTD sub-groups.

RESULTS: During the study period, 100 patients with confirmed COVID-19 underwent CTPA imaging. Ninety-three studies were analysed, excluding indeterminate CTPA examinations. Overall incidence of PTD was 41/93 (44%) with 28/93 patients showing small vessel PTD (30%). D-dimer was elevated in 90/93 (96.8%) cases. A high Wells' score did not differentiate between PTD and non-PTD groups (p=0.801). The interobserver agreement was fair (kappa=0.659) for parenchymal patterns and excellent (kappa=0.816) for severity. Thirty-four of the 93 cases (36.6%) had lymph node enlargement; 29/34 (85.3%) showed no additional source of infection. Sixteen of the 93 (17.2%) cases had potential fibrotic features.

CONCLUSION: There is a high incidence of PTD in COVID-19 patients undergoing CTPA and lack of a risk stratification tool. The present data indicates a higher suspicion of PTD is needed in severe COVID-19 patients. The concomitant presence of possible fibrotic features on CT indicates the need for follow-up.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Fang C, Garzillo G, Batohi B, et al. Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease. Clin Radiol. 2020. PMID: 32684301. doi:10.1016/j.crad.2020.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。